Annals of internal medicine

Adding oral semaglutide to usual treatment lowers major heart and blood vessel problems in high-risk type 2 diabetes over about 4 years

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

The abstract presents multiple specialized formulas related to cardiology, endocrinology, and nephrology.

  • Formulas for different medical fields may provide insights into patient care.
  • Cardiology formulas focus on heart-related metrics and their implications.
  • Endocrinology formulas address hormonal functions and their effects on health.
  • Nephrology formulas relate to kidney function and associated disorders.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosures: Disclosure forms are available with the article online.
PubMed

Related papers

Sep '25
Semaglutide may increase maximum walking distance after 1 year in people with peripheral artery disease and type 2 diabetes
top 2% journal
journal article
Sep '25
Weekly semaglutide improves liver inflammation and scarring in moderate to advanced fatty liver disease after 72 weeks
top 2% journal
journal article
Apr '25
Possible effects of semaglutide 2.4 mg on people with obesity or overweight and heart disease: A study using data from the SELECT trial
top 5% journal
cited by 9 papers
journal article
Sep '25
Lower heart and blood vessel event risk in real-world patients starting semaglutide 2.4 mg
top 5% journal
cited by 8 papers
observational study
Dec '24
How well oral semaglutide works when added to or replacing other incretin drugs in type 2 diabetes
top 20% journal
journal article
Mar '21
Cost-effectiveness of adding oral semaglutide to existing type 2 diabetes treatments
top 20% journal
cited by 12 papers
journal article
Dec '25
Heart health effects of Semaglutide compared to Dulaglutide in Type 2 diabetes
top 20% journal
comparative study
Dec '25
Oral semaglutide and heart-related health in people with type 2 diabetes: findings from the SOUL trial
top 10% journal
cited by 1 paper
journal article
Oct '20
Semaglutide’s impact on heart-related event risk across different levels of heart disease risk
top 2% journal
cited by 44 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief